AWHL (Aspira Womens Health) LT-Debt-to-Total-Asset: 0.38 (As of Mar. 2026)

What is Aspira Womens Health LT-Debt-to-Total-Asset?

Aspira Womens Health AWHL +7.07% 36 LT-Debt-to-Total-Asset is 0.38 as of Mar. 2026. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Aspira Womens Health's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.38.

Aspira Womens Health's long-term debt to total assets ratio increased from Mar. 2025 (0.35) to Mar. 2026 (0.38). It may suggest that Aspira Womens Health is progressively becoming more dependent on debt to grow their business.

Aspira Womens Health (OTCPK:AWHL) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Aspira Womens Health LT-Debt-to-Total-Asset Related Terms

Aspira Womens Health LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Aspira Womens Health's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aspira Womens Health LT-Debt-to-Total-Asset Chart

Aspira Womens Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.08

0.15

0.30

0.46

0.38

Aspira Womens Health Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.35	0.46	0.30	0.38	0.38

36GF Score

Aspira Womens Health Inc AWHL

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Aspira Womens Health LT-Debt-to-Total-Asset Calculation

Aspira Womens Health's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	2.049	/	5.456
	=	0.38

Aspira Womens Health's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	1.936	/	5.088
	=	0.38

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.38 mean?

Aspira Womens Health (AWHL) has a LT-Debt-to-Total-Asset of 0.38 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aspira Womens Health and its competitors.

Is Aspira Womens Health's LT-Debt-to-Total-Asset too high?

Aspira Womens Health's current LT-Debt-to-Total-Asset is 0.38. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Aspira Womens Health's LT-Debt-to-Total-Asset compare to MDXH and BIOQ?

Aspira Womens Health's LT-Debt-to-Total-Asset of 0.38 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Diagnostics & Research company?

A good LT-Debt-to-Total-Asset depends on the Medical Diagnostics & Research industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Aspira Womens Health and its competitors. Aspira Womens Health's current LT-Debt-to-Total-Asset is 0.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Aspira Womens Health stock overvalued right now?

Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.42 — trading 50% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.38. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current LT-Debt-to-Total-Asset is 0.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aspira Womens Health (AWHL) Overvalued in 2026?

Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued. The current stock price of $0.42 is trading 50% above its estimated GF Value™ of $0.28. GuruFocus considers Aspira Womens Health to be Significantly Overvalued.

Key valuation signals for AWHL:

LT-Debt-to-Total-Asset: 0.38
GF Value™: $0.28 vs. price of $0.42 (50% above fair value)
GF Score™: 36/100 with 7 warning signs

No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aspira Womens Health Business Description

Industry Healthcare Medical Diagnostics & Research

Comparable Companies MDXH BIOQ XWEL MBAI ADVB NDRA BIAF QUCY ISPC FUNI TMO DHR SHSE:603259 XSWX:LONN IDXX A NTRA WAT IQV ILMN

Address 12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738

Website https://www.aspirawh.com

Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.

36GF Score

Get the complete analysis for AWHL

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.42

Price

$0.28

GF Value

View AWHL Analysis

See LT-Debt-to-Total-Asset data for all stocks →